Adaptation of an rVSV Ebola Vaccine Purification Process for Rapid Development of a Viral Vaccine Candidate for SARS-CoV-2
Merck and IAVI adapted the ERVEBO® downstream process for an rVSVΔG-SARS-CoV-2 candidate. Formulating with InVitria recombinant human serum albumin before sterile filtration raised viral potency step yield from 42% to 74%.
Published
Nov 2026